3rd Annual Next Gen Immuno-Oncology Congress

3rd Next Gen Immuno-Oncology Congress
14-15 March 2019 in London

Over the past several years, many immuno-oncology modalities have emerged. These modalities, which include checkpoint inhibition, adoptive T-cell therapy (ACT), and cancer vaccines, are often designed to evade immune responses. This is a rapidly growing therapeutic field that embraces the concept of modulating the immune system to recognize tumor cells and target them for destruction. Our Next Gen Immuno-Oncology Congress from past 2 years had gathered the professionals across the globe to deliver such latest developments.

3rd Annual Next-Gen Immuno-Oncology Congress gathering C-suite professional, researchers and scientists from pharma, Biopharma, Biotech companies along with leading Research institutes and Academia. The two-day event held on 14 -15 March 2019 in London – UK will host 50+ presentations discussing latest updates in development of ADC’s, Bispecific Antibodies, Immune Checkpoint Inhibitors and Adoptive Cellular Therapy.

MabDesign Members benefit of 25% discount when registering. Ask us the code !


March 14-15, 2019


London, UK